Jan 21, 2025 7:30 am EST Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Jan 16, 2025 8:30 am EST Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Nov 27, 2024 4:01 pm EST Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Nov 13, 2024 4:01 pm EST Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
Nov 12, 2024 4:01 pm EST Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Nov 05, 2024 4:01 pm EST Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Oct 04, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 06, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 04, 2024 4:01 pm EDT Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference